Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer’s disease

Cellular senescence has been identified as a pathological mechanism linked to tau and amyloid beta (Aβ) accumulation in mouse models of Alzheimer’s disease (AD). Clearance of senescent cells using the senolytic compounds dasatinib (D) and quercetin (Q) reduced neuropathological burden and improved c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzales, Mitzi M., Garbarino, Valentina R., Kautz, Tiffany, Palavicini, Juan Pablo, Lopez-Cruzan, Marisa, Dehkordi, Shiva Kazempour, Mathews, Julia, Zare, Habil, Xu, Peng, Zhang, Bin, Franklin, Crystal, Habes, Mohamad, Craft, Suzanne, Petersen, Ronald C., Tchkonia, Tamara, Kirkland, James, Salardini, Arash, Seshadri, Sudha, Musi, Nicolas, Orr, Miranda E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168460/
https://www.ncbi.nlm.nih.gov/pubmed/37162971
http://dx.doi.org/10.21203/rs.3.rs-2809973/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168460/
https://www.ncbi.nlm.nih.gov/pubmed/37162971
http://dx.doi.org/10.21203/rs.3.rs-2809973/v1

Ejemplares similares